Ferreira et al68 designed a peptide named SAMβA that selectively antagonizes the association between beta II protein kinase C (βIIPKC) and Mfn1 to deactivate Mfn1, thus attenuating heart failure after MI. Here, MFN1 is linked to myocardial infarction.